ELEKTA AB/ADR (EKTAY) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company’s offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden. “

Separately, UBS Group upgraded shares of ELEKTA AB/ADR from a neutral rating to a buy rating in a research note on Wednesday, November 28th.

EKTAY opened at $12.52 on Tuesday. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 0.63. ELEKTA AB/ADR has a 52-week low of $8.46 and a 52-week high of $14.61. The company has a market cap of $4.61 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 2.67 and a beta of 0.40.


Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.

Featured Article: NASDAQ

Get a free copy of the Zacks research report on ELEKTA AB/ADR (EKTAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply